Thu 06/16/2022 12:50 PM
Share this article:
Relevant Item:
Endo Stakeholder Analysis Download on Reorg Analysis Tab

Endo’s first-quarter results and second-quarter guidance, in which the company disclosed $155.9 million in first-quarter Vasostrict sales, down 30.4% year over year, and said that second-quarter Vasostrict sales would fall by about 85% sequentially, appear to have substantially changed the way the market is evaluating a potential restructuring of the company. The deterioration in fundamentals also appears to have...
Share this article:
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.
Thank you for signing up
for Reorg on the Record!